Yvonne McGrath is VP at iTeos Therapeutics, Inc. (ITOS). They have made 5 open-market trades across 1 company since 2021, most recently 2025-08-29.
CIK 0001816213
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITOS | 46,300 | $470K |
Shares reported on the most recent Form 4, priced at the 2025-03-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITOS | SELL | 2022-03-01 | 2022-03-02 | $36.76 | $368K | +1.4% | -11.1% | -50.7% |
| ITOS | SELL | 2021-06-08 | 2021-06-10 | $20.00 | $159K | +14.8% | +27.4% | +43.8% |
| ITOS | SELL | 2021-06-01 | 2021-06-03 | $20.18 | $313K | +38.7% | +29.5% | +50.2% |
| ITOS | SELL | 2021-05-24 | 2021-06-03 | $21.92 | $348K | +38.7% | +29.5% | +50.2% |
| ITOS | SELL | 2021-05-17 | 2021-05-19 | $24.68 | $389K | -10.8% | +13.1% | +10.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.